These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 14685755

  • 1. Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: a rationale for the short-term use of class I drugs against triggered arrhythmias.
    Takahara A, Sugiyama A, Hashimoto K.
    Heart Vessels; 2004 Jan; 19(1):43-8. PubMed ID: 14685755
    [Abstract] [Full Text] [Related]

  • 2. Antiarrhythmic effects of bisaramil on triggered arrhythmias produced by intracoronary injection of digitalis and adrenaline in the dog.
    Haruno A, Hashimoto K.
    Jpn J Pharmacol; 1995 May; 68(1):95-102. PubMed ID: 7494388
    [Abstract] [Full Text] [Related]

  • 3. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS, Calzadilla SV, Diemer MJ, Hartman JC, Reynolds RD.
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [Abstract] [Full Text] [Related]

  • 4. Antiarrhythmic and cardiovascular profiles of the fused indole compound (3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydrox yisoquino [2,1,8-lma]carbazol-5(1H)-one hydrochloride 1.5 hydrate.
    Yorikane R, Mizuno H, Itoh Y, Koike H, Miyake S, Shiga H, Kumakura S, Fukami M, Shimoji Y, Hashimoto T.
    Arzneimittelforschung; 1991 Nov; 41(11):1130-6. PubMed ID: 1810258
    [Abstract] [Full Text] [Related]

  • 5. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
    Aupetit JF, Loufoua-Moundanga J, Faucon G, Timour Q.
    Br J Pharmacol; 1997 Feb; 120(3):523-9. PubMed ID: 9031759
    [Abstract] [Full Text] [Related]

  • 6. Frequency-dependent effects of class I, III and IV antiarrhythmic drugs on the conduction and excitability in rabbit ventricular muscle.
    Varró A, Bódi I, Jednákovits A, Rabloczky G.
    Arch Int Pharmacodyn Ther; 1988 Feb; 292():157-65. PubMed ID: 3395167
    [Abstract] [Full Text] [Related]

  • 7. Effect of antiarrhythmic drugs on the premature action potential duration in canine cardiac Purkinje fibers.
    Varro A, Elharrar V, Surawicz B.
    J Pharmacol Exp Ther; 1985 May; 233(2):304-11. PubMed ID: 3999021
    [Abstract] [Full Text] [Related]

  • 8. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P, Tegelkamp R, Osada N, Schimpf R, Wolpert C, Breithardt G, Borggrefe M, Eckardt L.
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [Abstract] [Full Text] [Related]

  • 9. Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction.
    Lynch JJ, Wallace AA, Stump GL, Stupienski RF, Kothstein T, Gehret JR.
    J Pharmacol Exp Ther; 1996 May; 277(2):671-8. PubMed ID: 8627544
    [Abstract] [Full Text] [Related]

  • 10. [Effects of several anti-arrhythmia agents on excitability and conduction depressed by digitalis agents].
    Márquez M, Kabela E.
    Arch Inst Cardiol Mex; 1984 May; 54(6):535-44. PubMed ID: 6241458
    [Abstract] [Full Text] [Related]

  • 11. Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165.
    Hashimoto K, Ishii M, Komori S, Mitsuhashi H.
    Heart Vessels; 1985 Feb; 1(1):29-35. PubMed ID: 2419304
    [Abstract] [Full Text] [Related]

  • 12. Combination ethacizin and ethmozin treatment of resistant ventricular ectopy: theoretical, experimental, and clinical study.
    Nesterenko VV, Anyukhovsky EP, Bugrij EM, Starmer CF, Beloshapko GG, Makielski JC, Kuzmin AV, Menshikov MJu, Mazaev AV, Rosenshtraukh LV.
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):501-8. PubMed ID: 7515997
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
    Gomoll AW.
    Arzneimittelforschung; 1987 Jul; 37(7):787-94. PubMed ID: 3118889
    [Abstract] [Full Text] [Related]

  • 17. Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
    Xue YX, Arita J, Aye NN, Hashimoto K.
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Dec; 358(6):649-56. PubMed ID: 9879724
    [Abstract] [Full Text] [Related]

  • 18. [Estimation of depressant effects of class I antiarrhythmic drugs on intraventricular conduction--rate-dependent effects on QRS duration].
    Ikeda N, Kamiya K.
    Jpn Circ J; 1992 Dec; 56 Suppl 5():1477-9. PubMed ID: 1337924
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.